ArticleFrontiers in public health2021
Economic Burden of Major Diseases in China in 2013.
Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The economic burden of ischaemic heart diseases on health systems: a systematic review.BMJ global health · 2025Pooled it
- Article
- Economic evaluation of telemedicine-based integrated management of atrial fibrillation in rural China: a modeling analysis.NPJ digital medicine · 2026Article
- The influence of habitual tooth brushing frequency on individuals diagnosed with coronary artery disease.Scientific reports · 2025Article
- The impact of economic burden of disease on poverty among young migrant workers: evidence from China.Frontiers in public health · 2025Article
- Spatiotemporal inequality and financial toxicity of leukemia in post-poverty China: a national analysis of 832 counties (2019-2024).Frontiers in public health · 2025Article
- Projections of Socioeconomic Costs for Individuals with Dementia in China 2020-2050: Modeling Study.Journal of Alzheimer's disease : JAD · 2024Article
- Research on the influence of patient cost-sharing on medical expenses and health outcomes: Taking patients with heart failure as an example.Frontiers in public health · 2023Article
- Impacts of short-term air pollution exposure on appendicitis admissions: Evidence from one of the most polluted cities in mainland China.Frontiers in public health · 2023Article
- Direct medical costs of ischemic heart disease in urban Southern China: a 5-year retrospective analysis of an all-payer health claims database in Guangzhou City.Frontiers in public health · 2023Article
- Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies on the economic burden of disease (EBD) can estimate the social benefits of preventing or curing disease. The majority of studies focus on the economic burden of a single or regional disease; however, holistic or national research is rare in China. Estimating the national EBD can provide evidence for policy makers. We used the top-down method to assess the economic burden of 30 types of diseases between urban and rural areas in China. The two-step model was used to evaluate the direct economic burden of disease (DEBD), while the human capital method was used to assess the indirect economic burden of disease (IEBD). The total economic burden of 30 types of diseases in China was between $13.39 and 803.00 billion in 2013. The average total economic burden of disease (TEBD) in cities was $81.39 billion, while diseases in villages accounted for $50.26 billion. The range of direct and indirect EBD was $5.77-494.52 billion, and the range in urban areas was $0.61-20.34 billion. The direct and indirect EBD in rural areas accounted for $5.88-277.76 billion and $0.59-11.39 billion, respectively. There was a large difference between the economic burden of different diseases. The economic burden of urban diseases was more significant than the burden for the rural. The top five most economically burdensome diseases were myocardial infarction coronary artery bypass, acute myocardial infarction, cerebral hemorrhage, acute upper gastrointestinal bleeding and acute appendicitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.